Starpharma Holdings Limited · ASX:SPL
Starpharma — Australian Microcap Investment Conference 2025
27 slides from Starpharma's conference presentation, Oct 21, 2025
Slide 1: ASX Announcement: Australian Microcap Investment Conference presentation
ASX Announcement Australian Microcap Investment Conference presentation Melbourne, Australia; 21 October 2025: Starpharma (ASX: SPL, US OTC: SPHRY), an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient, provides a copy of th
Slide 2: About Starpharma
Visit Starpharma’s new Investor Hub to access the latest company developments, updates, and strategic insights, and submit questions. By joining our Investor Hub, you will gain access to commentary from CEO Cheryl Maley and resources designed to help you stay connected with Starpharma’s story. Scan
Slide 3: Delivering meaningful patient outcomes with advanced dendrimer technology
For personal use only ASX : SPL US OTC : SPHRY Delivering meaningful patient outcomes with advanced dendrimer technology Australian Microcap Investment Conference 21 October 2025
Slide 4: Disclaimer and forward-looking statements
Disclaimer and forward-looking statements For personal use only This presentation contains forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, Starpharma can give no assura
Slide 5: At the cutting edge of drug delivery
For personal use only Starpharma is at the cutting edge of drug delivery, with validated dendrimer technology, strategic partnerships, global commercial reach, and a world- class team dedicated to delivering breakthrough health solutions. 3
Slide 6: Our mission
For personal use only Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology. 4
Slide 7: Investment highlights
Investment highlights Transforming drug delivery for lasting impact For personal use only Clinically validated Expanding Broad application Uniquely Strong intellectual DEP® platform commercialisation in high-value experienced team property position technology opportunities therapeutics More than 350
Slide 8: Corporate overview
Corporate overview An innovative, biopharmaceutical company and leader in dendrimer technology For personal use only Share price ASX:SPL Ticker US OTC: SPHRY ~A$0.28 Share Price (~USD$0.19) Market ~A$113M Capitalisation Total ordinary 418M shares on issue Pharmaceuticals, GICS classification Biotech
Slide 9: DEP® platform
For personal use only DEP® platform 7
Slide 10: DEP® dendrimers: a unique drug delivery technology
DEP® dendrimers A unique drug delivery technology For personal use only Dendrimers are highly branched (tree-like) macromolecules with a well-defined 3D structure. DEP® dendrimers are made up of concentric layers of lysine monomers (generations) that can be customised to carry payloads, drugs, and/o
Slide 11: Our DEP® platform technology: solving drug development challenges
Our DEP® platform technology Solving drug development challenges For personal use only Efficacy DEP® technology advantages which can help 50% address these challenges: • Targeted delivery: improves efficacy and reduces off- target toxicity. Top 3 • Versatile targeting: compatible with many types of
Slide 12: Harnessing multiple pathways to maximise shareholder returns
Our DEP® platform technology Harnessing multiple pathways to maximise shareholder returns For personal use only Novel asset Radiotheranostics, ADCs, combinations, non- development oncology molecules (revenue from asset license & commercialisation) DEP Platform Multinational, private equity, biotechn
Slide 13: Our competitive advantage
Our competitive advantage Setting the standard in drug delivery For personal use only Starpharma PAMAM Scaffold Properties Liposome DEP® Dendrimer Dendrimer Drug Loading Capacity Stability and Release Chemistry Encapsulation/conjugation Biodegradable Manage PK properties Immunogenicity/safety profil
Slide 14: Novel asset development
For personal use only Novel asset development 12
Slide 15: Our pipeline
Our pipeline Unlocking value through clinical-stage assets, partnerships, and marketed products For personal use only Internal DEP® Pipeline Partnered DEP® Programs Target Pre- Product Research Phase I Phase II Phase III Strategy indication clinical License/co- Ovarian and DEP® SN38 colorectal Clini
Slide 16: Pre-clinical validation of DEP® dendrimers
Pre-clinical validation of DEP® dendrimers Modifying generation (size) improves tumour accumulation via EPR, leading to improved efficacy For personal use only DEP® allows better targeting of Radiolabelled DEP® DEP® cabazitaxel shows drugs to cancer tissue resulting in dendrimer-drug conjugate enhan
Slide 17: Clinical validation: DEP® SN38 efficacy in late-stage patients
Clinical validation of DEP® dendrimers DEP® SN38 shows favourable efficacy in late-stage patients For personal use only Advanced Colorectal Cancer Advanced Platinum-Resistant Ovarian Cancer 14 10.4 4.2 43 2.8 4 3.4 11.8 mPFS (months) ORR (%) mPFS (months) ORR (%) Data for DEP® SN38 in combination wi
Slide 18: Clinical validation: DEP® SN38 tolerability in late-stage patients
Clinical validation of DEP® dendrimers DEP® SN38 shows favourable tolerability in late-stage patients For personal use only Gastrointestinal Toxicity Profile Significantly Improved with DEP® SN38 Treatment, Compared to Published Data on Irinotecan# 50% 47% 45% 40% 35% Only 1 patient with No cases of
Slide 19: Strategic opportunity in radiopharmaceuticals
Strategic opportunity in radiopharmaceuticals Creating differentiated assets with significant market potential For personal use only Why radiopharmaceuticals • Radiopharmaceuticals combine radioactive isotopes with targeting Starpharma’s HER2 strategy molecules to diagnose and treat cancer more prec
Slide 20: DEP® radiotheranostics
DEP® radiotheranostics Addressing the drug delivery challenges of current approaches For personal use only Biodistribution Challenges Starpharma’s DEP® Technology Solution: with Other Approaches: Tumour:Kidney/Organ DEP® HER2 radiodiagnostic: faster Tumour:Kidney ratio highly negative Tumour:Blood r
Slide 21: Strategic partnerships
For personal use only Strategic partnerships 19
Slide 22: Our strategic partnerships
Our strategic partnerships Expanding opportunities for commercialisation For personal use only Exclusive License Joint Venture Research and Agreement • Single asset focus Option Agreement • Limited targets, multi- • USD $25M investment • Single asset focus product by Medicxi • Deal value up to ~AUD
Slide 23: Recent media attention following GNE deal
Recent media attention following GNE deal Positioning DEP® as a next-gen oncology delivery platform beyond biologics For personal use only 21
Slide 24: Summary & outlook
For personal use only Summary & outlook 22
Slide 25: Our strategy & outlook
Our strategy & outlook Focusing on strategic execution & revenue generation For personal use only Three focused strategic imperatives Anticipated catalysts • Radiotheranostic progress to the clinic • License/collaboration for a DEP® asset to 01 02 03 commercialise Maximising Building Building long-
Slide 26: Why Invest in Starpharma?
Why Invest in Starpharma? Transforming drug delivery for lasting impact For personal use only Clinically Expanding Broad Uniquely Strong validated commercial application experienced intellectual DEP® opportunities in high-value team property platform therapeutics position technology 24
Slide 27: Thank you
For personal use only ASX : SPL US OTC : SPHRY Thank you. Investor Relations Corporate Office Investor.Relations@Starpharma.com 4 – 6 Southampton Crescent www.starpharma.com Abbotsford, Victoria 3067 Australia
Starpharma Holdings — Australian Microcap Investment Conference 2025 on 6ix